| 16-P | Adherence with baseline and follow-up screening for cataracts in patients on modulators containing ivacaftor. | conor ring | |
| 17-P | Cystic fibrosis newborn screening pilot study in Estonia | Elerin Albin | |
| 20-P | Critical assessment of newborn screening data in a low-income country: insights from a Brazilian reference center | Juliana Horn | |
| 23-P | Genome sequencing for discovery of hard-to-detect CFTR gene mutations | Jolt Roukema | |
| 25-P | Ethnic differences in the frequency of CFTR gene variants in the Russian Federation | Nataliya Kashirskaya | |
| 58-P | Paired culture-based analysis reveals heterogeneous airway microbiota restructuring after elexacaftor/tezacaftor/ivacaftor (ETI) therapy in adult people with cystic fibrosis (pwCF) | Kevin Deasy | |
| 84-P | Mycobacterium abscessus clearance post initiation of elexacaftor/tezacaftor/ivacaftor in patients with cystic fibrosis | Hannah Withers | |
| 110-P | The link between pulmonary exacerbations and respiratory viruses in young children with cystic fibrosis. | Kim Van Hoorenbeeck | |
| 129-P | Factors associated with response to CFTR modulator therapy in cystic fibrosis | Paulina Famulska | |
| 143-P | Long-term safety and efficacy of vanzacaftor/tezacaftor/deutivacaftor in people with cystic fibrosis aged 12 years and older: 96-week interim analysis from an open-label extension study | Dario Prais | |
| 144-P | Pregnancy and neonatal outcomes in women with cystic fibrosis receiving elexacaftor/tezacaftor/ivacaftor | Nele-Kristin Vagt | |
| 146-P | Model-informed dose reduction of elexacaftor/tezacaftor/ivacaftor therapy in adult people with cystic fibrosis: a simulation study | Syendon Baromeo | |
| 157-P | Exploring perspectives of patients receiving outpatient palliative care alongside usual CF treatment: A qualitative study within a Randomized Controlled Trial | Dio Kavalieratos | |
| 163-P | Discontinuing therapy in children with Cystic Fibrosis on CFTR modulators | Madalena Duarte | |
| 175-P | The "last families" in cystic fibrosis: equity, non-responders, and the translational imperative | Christopher Landon | |
| 185-P | Phase 2 population pharmacokinetics (popPK) of verducatib (BI 1291583) in people with cystic fibrosis and non-cystic fibrosis bronchiectasis (CFBE and NCFBE) | Keeley Sankey | |
| 198-P | Clinical utility of 129Xe ventilation Magnetic Resonance Imaging (MRI) in Paediatric Cystic Fibrosis (CF) patients | Ina Aldag | |
| 207-P | Prevalence and Perceptions of E-Cigarette Use Among Children and Adolescents With Cystic Fibrosis in a Canadian Cystic Fibrosis Center. | Candice Bjornson | |
| 218-P | Advancing Inclusive Enrollment: Insights from the LTx READY CF 2 Study | Tijana Milinic | |
| 231-P | Early vascular dysfunction in adults with cystic fibrosis: a controlled observational study | Bruno Porto Pessoa | |
| 236-P | The role of physical activity in bone health among people with cystic fibrosis: a scoping review | Ziyad Alharbi | |
| 239-P | Cardiopulmonary exercise testing in three cystic fibrosis patients with at least one copy of the F508del CFTR mutation and normal distance on the six-minute walk test. | Paulo Mendes | |
| 249-P | Comparing Airway Sampling Methods in Non-Expectorating Children with Cystic Fibrosis and Bronchiectasis | Ayesha Delaney | |
| 276-P | Assessment of abdominal symptoms and intestinal inflammation in children and adolescents with cystic fibrosis before and after initiation of elexacaftor/tezacaftor/ivacaftor therapy | Gabriel Cezar dos Santos | |
| 293-P | Patterns of referral, investigation, and diagnosis in a specialist adult cystic fibrosis gastroenterology service | Penelope Ward-Hutchings | |
| 298-P | Intestinal inflammation in pediatric cystic fibrosis - Impact of elexacaftor/tezacaftor/ivacaftor therapy | Camilla Sland | |
| 300-P | Traditional cardiometabolic risk factors trajectories before and after Elexacaftor/Tezacaftor/Ivacaftor initiation | Heather Girouard | |
| 302-P | Trends in emergency department visits and hospitalizations for gastrointestinal complications in pediatric patients with cystic fibrosis pre and post modulator therapy: a multicenter analysis | Christiana Ekezie | |
| 325-P | The Impact of Elexacaftor/Tezacaftor/Ivacaftor on Bone Mineral Density in Children and Adults with Cystic Fibrosis | David OKeeffe | |
| 330-P | Reviewing the necessity for annual liver ultrasounds in children with cystic fibrosis - A comparison to the Cystic Fibrosis Standards of Care | Jessamy Coulson | |
| 331-P | Comparison of carbohydrate metabolism in children with cystic fibrosis with and without variant-specific therapy | Lyabina Nadezhda | |
| 337-P | Impact of Early Elexacaftor/Tezacaftor/Ivacaftor Treatment on Growth and Pancreatic Function in Children with Cystic Fibrosis | Miriam Mala | |
| 351-P | Service evaluation of a virtual ´vitamin club´ for optimising fat-soluble vitamin management in children with cystic fibrosis | Mary Healy | |
| 372-P | Medical traumatic stress in cystic fibrosis: National survey of provider knowledge, barriers and clinical practice | Alexandra Quittner | |
| 373-P | Correlation of substance use among adolescent cystic fibrosis patients with mental health screenings using CRAFFT, PHQ-9, and GAD-7 screening tools. | Sara Hill | |
| 377-P | Psychometric validation of the General Mental Health Screener and Modulator Side-Effects instruments: Novel research design | Alexandra Quittner | |
| 378-P | ACT with CF Self-Help Toolkit: a Standalone Targeted Mental Health Intervention for Adults with Cystic Fibrosis | Meredith Marden | |
| 384-P | Identifying Patient - Reported Care Needs in an Adult Cystic Fibrosis Service | Ciara Quigney | |
| 388-P | Meeting the need when it matters most: Creating a unique, specialist out-of-hours cystic fibrosis (CF) multidisciplinary team (MDT) on-call service at the York Hull CF Centre. | Kath France | |
| 391-P | Digital Transformation of paediatric cystic Fibrosis Care: A Cost-Benifit Evaluation | Frida Lundqvist | |
| 397-P | ´Mum Culture´ in Hospital Care: An Interpretative Phenomenological Analysis of Identity, Scrutiny, and Coping Among Mothers of Children with Cystic Fibrosis. | Ruth Day | |
| 399-P | Understanding the evolving needs of the cystic fibrosis (CF) community in Australia: challenges, priorities and opportunities | Genevieve Handley | |
| 406-P | Patient-provider communication and shared decision-making in CF pain management | Deborah Friedman | |
| 432-P | Demographic and clinical characteristics of children with CF aged 2-5 years initiating ELX/TEZ/IVA in LONGITUDE a UK CF Registry observational study | Lorilei Richardson | |
| 446-P | Uruguayan Experience with the Use of CFTR Modulators in the Pediatric Population | Maria Catalina Pinchack | |
| 458-P | Pregnancy care and outcomes in patients with cystic fibrosis at a UK specialist centre | Adelaide Yue | |
| 467-P | Positive airway pressure initiation is associated with improved lung function in persons with cystic fibrosis. | Nicholas Vozoris | |
| 472-P | Audiological profiling in an era of CFTR modulation, including extended high frequency hearing assessment in a cohort of adult people with Cystic Fibrosis (pwCF). Preliminary results of 104 screened. | Kevin Deasy | |
| 474-P | Newborn Screening and Early Outcomes in Cystic Fibrosis: ECFS Patient Registry Data | Laura Kirwan | |
| 478-P | A Low-Cost, Standardized Cystic Fibrosis Registry Architecture for Low- and Middle-Income Countries: The International Cystic Fibrosis Training Network (ICFTN) Experience | Cathy Mims | |
| 479-P | Evaluation of professional quality of life and prevalence of burnout: A national survey of healthcare providers on cystic fibrosis (CF) care teams | Alexandra L. Quittner | |
| 482-P | A mixed-methods evaluation of the International Cystic Fibrosis Training Network program, a multidisciplinary training model to improve cystic fibrosis care in low- and middle-income countries | Cathy Mims | |
| 483-P | Advancing cystic fibrosis care in Canada: developing a national quality improvement model | Jana Kocourek | |
| 484-P | The role of the Paediatrician in managing patients with cystic fibrosis in the absence of specialised centers | Lola Dzhumaeva | |
| 485-P | Building and implementing a data core team to support a cystic fibrosis learning network. | Bethany Horton | |
| 489-P | Updating the Cystic Fibrosis Questionnaire-Revised (CFQ-R) in the era of highly effective modulators: A qualitative and crosswalk study to develop the CFQ-M | Alexandra L. Quittner | |
| 490-P | Mapping current practice & preferences in the use of PROMs in the clinical setting in Ireland and an international review of the inclusion of PROMs in Cystic Fibrosis patient registries | Laura Kirwan | |
| 493-P | How to deliver Digital Health Literacy Training to PwCF, Families, and Caregivers: results of an Irish Survey | Tamara Vagg | |
| 494-P | Cloud-based remote care for cystic fibrosis: feasibility and patient outcomes | Benedicte Akselsen Grĝterud | |
| 495-P | Mapping current practices of digital health in respiratory disease management: national survey | Hibbah Alshuwaikhat | |
3-6 June, 2026 Lisbon

Digital Object Identifier. Official code used to identify documents published on internet; similar to ISBN for books. You may use this code to reference your poster in future scientific publications or CVs. It can be found from anywhere in the world. To find the poster page, log onto www.medra.org and enter the DOI, or enter in your internet browser https://dx.doi.org/ followed by the DOI string asigned to your congress. |
||||
|
|